The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Acalabrutinib monotherapy and in combination with rituximab in patients with FL
|
Results from a multicenter, open-label phase Ib/II trial (NCT02180711) that evaluated the safety and efficacy of acalabrutinib, a second-generation BTK inhibitor, alone or in combination with rituximab in patients with FL have been published in the British Journal of Haematology by Strati et al.1
|
| Key learnings |
| The most common any grade AEs in the acalabrutinib + rituximab TN cohort, acalabrutinib monotherapy R/R cohort, and acalabrutinib + rituximab R/R cohort included hypertension (25%, 7,7%, 15.4%) and diarrhea (41.7%, 38.5%, 53.8%), while SAEs were reported in 16.7%, 38.5%, 23.1%, respectively. |
| The ORR rates were 92.3%, 33.3%, and 30.8% in the acalabrutinib + rituximab TN, acalabrutinib monotherapy R/R, and acalabrutinib + rituximab R/R cohorts, respectively, and the CR rates were 38.5%, 8.3%, and 15.4%. |
| Overall, the efficacy and safety data suggest that acalabrutinib monotherapy and in combination with rituximab could be a viable treatment option for patients with FL. |
Abbreviations: AE, adverse event; BTK, Bruton’s tyrosine kinase; CR, complete response; FL, follicular lymphoma; ORR, overall response rate; R/R, relapsed/refractory; SAE, serious adverse event; TN, treatment naïve.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
